Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Long-Term Extension Trial With Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants With Major Depressive Disorder (EXTEND)

Next Previous
Search
Trial Profile

A Phase III Long-Term Extension Trial With Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants With Major Depressive Disorder (EXTEND)

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYB 003 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms EXTEND
  • Sponsors Cybin

Most Recent Events

  • 22 Apr 2025 Planned number of patients changed from 550 to 468.
  • 22 Apr 2025 Planned End Date changed from 6 Sep 2027 to 15 Jan 2028.
  • 22 Apr 2025 Planned primary completion date changed from 6 Sep 2027 to 15 Jan 2028.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top